capAI raises £280K to fund AI health and media platforms
What's the deal? capAIDealroom has a profile for this one. Try Dealroom →, an applied artificial intelligence venture platform listed on the London Stock Exchange (LSE: CPAI), has raised £280,000 in gross proceeds through a placing and a share subscription. Executive Chairman Professor Ronjon NagDealroom has a profile for this one. Try Dealroom → contributed £25,000, agreeing to buy 5,555,555 new ordinary shares.
The terms: Shares were issued at 0.45 pence each, with one warrant granted per new share, exercisable at 1 pence within 12 months of admission. The placing was coordinated by broker AlbR Capital.
What's the endgame? Net proceeds will support development of capAI's capMedical and capMedia platforms, plus general working capital.
capMedical centres on Ageotype, an AI-powered longevity and preventative health platform licensed from R42 GroupDealroom has a profile for this one. Try Dealroom → under an agreement announced on July 23, 2026. capMedia covers the Author42, Movie42, and Gamers42 licences, extended with R42 Group on July 9, 2026.
Why it matters: Nag's own subscription signals continued alignment with shareholders. Following admission, capAI will have 491,321,950 voting rights.
The signal: The raise is modest, but it keeps capAI's capital-light venture model moving across health and media as it builds out its first platforms in each vertical.
Read more: Investegate
Image credit: Rawpixel Ltd
